Publications by authors named "Christopher Darus"

Claim this Profile
C
Corrigendum to "OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer" [Gynecol Oncol 2025 Jun 197 182-191].
Premal H Thaker, Debra L Richardson, Andrea R Hagemann, Robert W Holloway, Mark Reed, Christopher J Darus

Gynecol Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer.
Premal H Thaker, Debra L Richardson, Andrea R Hagemann, Robert W Holloway, Mark Reed, Christopher J Darus

Gynecol Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial.
Ann H Klopp, Danielle Enserro, Matthew Powell, Marcus Randall, Julian C Schink, Christopher J Darus

J Clin Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).
Kathleen N Moore, Michael Bookman, Jalid Sehouli, Austin Miller, Charles Anderson, Christopher J Darus

J Clin Oncol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of geography and travel distance on outcomes in epithelial ovarian cancer: a national cancer database analysis.
Ava Daruvala, F Lee Lucas, Jesse Sammon, Christopher Darus, Leslie Bradford

Int J Gynecol Cancer· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
Ursula A Matulonis, Michael W Sill, Vicky Makker, David G Mutch, Jay W Carlson, Christopher J Darus

Gynecol Oncol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre-operative assessment and post-operative outcomes of elderly women with gynecologic cancers, primary analysis of NRG CC-002: An NRG oncology group/gynecologic oncology group study.
Amina Ahmed, Wei Deng, William Tew, David Bender, Robert S Mannel, Christopher J Darus

Gynecol Oncol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
Bradley J Monk, Michael W Sill, Joan L Walker, Christopher J Darus, Gregory Sutton

J Clin Oncol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial.
Kathleen N Moore, Michael W Sill, Meaghan E Tenney, Christopher J Darus, David Griffin

Gynecol Oncol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
David Bender, Michael W Sill, Heather A Lankes, Henry D Reyes, Christopher J Darus

Gynecol Oncol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N.
Vicky Makker, Virginia L Filiaci, Lee-May Chen, Christopher J Darus, James E Kendrick

Gynecol Oncol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of primary breast cancer of the vulva with hereditary breast and ovarian cancer.
Amanda Lamb, Christopher J Darus, Silvia Skripenova, Tracey Weisberg, Susan Miesfeldt

J Clin Oncol· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and impact of human papillomavirus vaccines.
Christopher J Darus, Jennifer J Mueller

Clin Obstet Gynecol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surgical management and postoperative treatment of endometrial carcinoma.
Jason A Lachance, Christopher J Darus, Laurel W Rice

Rev Obstet Gynecol· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclooxygenase-2 in cervical neoplasia: a review.
Jennifer L Young, Amir A Jazaeri, Christopher J Darus, Susan C Modesitt

Gynecol Oncol· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Use of p16 in enhancing the histologic classification of uterine smooth muscle tumors.
Kristen A Atkins, Nora Arronte, Christopher J Darus, Laurel W Rice

Am J Surg Pathol· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis